RECORD // Company

Korro Bio, Inc.

Formerly: Frequency Therapeutics, Inc.

Built 2026-11-21T11:53:40Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (3)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Korro Bio, Inc. · Ctgov · same registered legal name as 'Korro Bio, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • KORRO BIO INC · Epa echo · same registered legal name as 'Korro Bio, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • KORRO BIO INC · Epa echo · same registered legal name as 'Korro Bio, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001193125-26-448550

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-050001193125-26-4485502026-11-21 11:53 UTCReport an error
Net income (loss)$-17,548,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4485502026-11-21 11:53 UTCReport an error
Cash and cash equivalents$40,215,000at 2026-09-3010-Q2026-11-050001193125-26-4485502026-11-21 11:53 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001703647
Ticker
KRRO
EIN
472324450
CUSIP
500946108
Record ID
sx:sec:0001703647

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 11:53 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 11:53 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 11:53 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 11:53 UTCReport an error
Business address60 FIRST STREET, 2ND FLOOR, SUITE 250, CAMBRIDGE, MA, 021412026-11-16SEC EDGAR company profile2026-11-21 11:53 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 11:53 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$6,392,0002025-12-3110-K, XBRL Revenues2026-11-21 11:53 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-117,260,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:53 UTCReport an error
Total assets (at 2025-12-31)$113,506,0002025-12-3110-K, XBRL Assets2026-11-21 11:53 UTCReport an error
Stockholders' equity (at 2025-12-31)$51,439,0002025-12-3110-K, XBRL StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest2026-11-21 11:53 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$21,824,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:53 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-78,561,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:53 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$518,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:53 UTCReport an error
Operating lease liabilities (at 2025-12-31)$43,486,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:53 UTCReport an error
Form D total offering amount (D filed 2020-07-27)$42,301,9442020-07-27D2026-11-21 11:53 UTCReport an error
Form D total amount sold (D filed 2020-07-27)$42,301,9442020-07-27D2026-11-21 11:53 UTCReport an error
Form D industry groupBiotechnology2020-07-27D2026-11-21 11:53 UTCReport an error
Form D revenue rangeDecline to Disclose2020-07-27D2026-11-21 11:53 UTCReport an error
Form D date of first sale2020-07-202020-07-27D2026-11-21 11:53 UTCReport an error
8-K Item 1.02, Termination of a Material Definitive Agreement (filed 2026-11-05)On November 3, 2026, Korro Bio, Inc., or Korro, received written notice from Novo Nordisk A/S, or Novo Nordisk, of Novo Nordisk’s election to terminate for convenience the research collaboration and license agreement between Korro and Novo Nordisk dated September 13, 2024, as amended on November 11, 2025, or the collaboration and license agreement. Under the collaboration and license agreement, Novo Nordisk may terminate the agreement without cause upon 90 days’ prior written notice. The termination will be effective on February 1, 2027, or the termination date. Under the collaboration and license agreement, Korro granted Novo Nordisk an exclusive worldwide license under certain…2026-11-05SEC EDGAR 8-K 0001193125-26-448532 (text as filed, excerpt)2026-11-21 11:53 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Korro issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.2026-11-05SEC EDGAR 8-K 0001193125-26-448532 (text as filed, excerpt)2026-11-21 11:53 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-22)On October 22, 2026, Korro Bio, Inc. issued a press release announcing preclinical results for KRRO-111, its development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.2026-10-22SEC EDGAR 8-K 0001193125-26-428306 (text as filed, excerpt)2026-11-21 11:53 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-05)On October 5, 2026, Korro Bio, Inc. issued a press release announcing that it has dosed the first cohort of participants in ANCHOR, its Phase 1/2 clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.2026-10-05SEC EDGAR 8-K 0001193125-26-414118 (text as filed, excerpt)2026-11-21 11:53 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-19)On August 19, 2026, Korro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders, or UCDs. The purpose of the Phase 1/2 clinical trial for KRRO-121 is to determine the safety and tolerability of escalating doses, evaluate its pharmacokinetics, and assess its effect in healthy volunteers and in study participants with UCDs. For additional information, visit ClinicalTrials.gov (NCT 07773246). Forward-Looking Statements Certain statements…2026-08-19SEC EDGAR 8-K 0001193125-26-356877 (text as filed, excerpt)2026-11-21 11:53 UTCReport an error
Largest institutional holder #1 (13F as filed): Lynx1 Capital Management LP$20,274,7412026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #2 (13F as filed): Nantahala Capital Management, LLC$17,398,5482026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #3 (13F as filed): NEA Management Company, LLC$17,106,2302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #4 (13F as filed): Venrock Adviser, LLC$13,305,2102026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #5 (13F as filed): Atlas Venture Life Science Advisors, LLC$12,690,8112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #6 (13F as filed): Balyasny Asset Management L.P.$12,544,5002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #7 (13F as filed): BlackRock, Inc.$10,776,2452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #8 (13F as filed): Affinity Asset Advisors, LLC$9,316,9952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #9 (13F as filed): ADAGE CAPITAL PARTNERS GP, L.L.C.$7,129,9582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error
Largest institutional holder #10 (13F as filed): ADAR1 Capital Management, LLC$7,117,9122026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:53 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.